

CHOLESTEROL MEDICATIONS

(Updated 03/30/2022)

I. CODE OF FEDERAL REGULATIONS - 67.113(c); 67.213(c); and 67.313(c)

II. MEDICAL HISTORY: Item 37: Vascular System

The applicant should provide history as to why the medication is used. If taken for a cardiac condition, see that section. The AME should inquire if the applicant has ever experienced any side effects that could interfere with aviation safety.

III. AEROMEDICAL DECISION CONSIDERATIONS:

See Item 37: Vascular system

IV. PROTOCOL: N/A

V. PHARMACEUTICAL CONSIDERATIONS

- Cholesterol Medication
 - All drug classes require the minimum standard 48-hour initial ground trial.

ACCEPTABLE (As a single agent or in any combination product.)	
✓ HMG-CoA reductase inhibitor <ul style="list-style-type: none"> • atorvastatin (Lipitor; Sortis [INTL]) • fluvastatin (Lescol) • lovastatin (Altoprev) • pravastatin (Pravachol) • rosuvastatin (Crestor) • simvastatin (Zocor) 	✓ Fibric Acid <ul style="list-style-type: none"> • fenofibrate (Antara, Tricor, Triglide, Trilipix) • gemfibrozil (Lopid)
	✓ Bile Acid Sequestrant <ul style="list-style-type: none"> • cholestyramine (Prevalite; Questran) • colesevelam (Welchol) • colestipol (Colestid)
✓ Omega-3-acid ethyl esters <ul style="list-style-type: none"> • omega-3-acid ethyl esters (Lovaza) • icosapent ethyl (Vascepa) 	✓ Adenosine Triphosphate-Citrate Lyase (ACL) Inhibitor <ul style="list-style-type: none"> • bempedoic acid (Nexletol)
✓ Nicotinic acid <ul style="list-style-type: none"> • niacin (Niaspan) 	✓ 2-Azetidinone <ul style="list-style-type: none"> • ezetimibe (Zetia)

CONDITIONALLY ACCEPTABLE	
Medication	Post-dose observation (no-fly time after each dose)
Monoclonal Antibody - PCSK9 Inhibitor <ul style="list-style-type: none"> • alirocumab (Praluent) • evolocumab (Repatha) 	4 hours

UNACCEPTABLE	
Apolipoprotein B Antisense Oligonucleotide <ul style="list-style-type: none"> • mipomersen (Kynamro) 	